CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.

CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics is a biopharmaceutical company with operations in China and the U.S. focused on developing innovative CAR T-cell therapies for the treatment of hematological malignancies and solid tumors.

CARsgen Therapeutics

CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.

Media contact: pr@carsgen.com

JIC Genesis Fountain Healthcare Ventures

Kaitai Capital

Summer Capital

Lilly Asia Ventures

Loyal Valley Capital

Shiyu Capital

South China Venture Capital

Photon Fund

Jolly Innovation Ventures

KTB Ventures

"In the past six months, we have made significant progresses in technological innovation, product development, and business operations. Zevor-cel was successfully launched in China and has been included in nearly 20 provincial and municipal healthcare plans. The pivotal Phase II trial of satri-cel in China has completed patient enrollment. We are also actively exploring the potential of satri-cel in adjuvant therapy, aiming for greater clinical benefit for patients. Additionally, we are rapidly advancing CT071, which is manufactured with our CARcelerate® platform, while continuing to develop multiple allogeneic CAR T-cell products based on the THANK-uCAR® platform." said Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics.

https://lnkd.in/gmubHD2Y

#cartcelltherapy #biotech #hematology #oncology

"We are very pleased to announce the successful completion of patient enrollment in the pivotal Phase II clinical trial of satri-cel in China. This significant milestone marks another solid step forward in our development of CAR T-cell therapies for solid tumors. We extend our gratitude to all the investigators, the patients and their families for their trust and support. We look forward to the submission of New Drug Application and the approval in China, to benefit patients with gastric cancer. As one of the leading companies in the field of CAR T-cell therapies, we remain committed to addressing the major challenges faced by existing CAR T-cell therapies and will develop more innovative CAR-T products for cancer patients." said Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics.

https://lnkd.in/gZjZdQZa

The updated results of zevorcabtagene autoleucel (zevor-cel; R&D code: CT053, an autologous CAR T-cell product targeting BCMA) and CT071 (an autologous CAR T-cell product targeting GPRC5D) have been presented at the 29th Annual Congress of the European Hematology Association (“EHA”). 

https://lnkd.in/gEKkNrwb

#cartcelltherapy #eha2024 #multiplemyeloma #bcma #gprc5d #carcelerate

The preliminary results of Phase I of CT071 (NCT05838131) were presented as a poster at the 29th EHA Annual Congress on June 14, 18:00 - 19:00 CEST, which was titled "First-in-human study of GPRC5D-targeted CAR T cells (CT071) with an accelerated manufacturing process in patients with relapsed/ refractory multiple myeloma (RRMM)"

https://lnkd.in/g3R_eYun

#eha #eha2024 #rrmm #cartcelltherapy #gprc5d

The final follow-up results of the investigator-initiated trial CT041-CG4006 (NCT03874897) of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18.2) have been published in Nature Medicine on June 3, 2024. Data were presented as an oral presentation at the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting.

https://lnkd.in/gnsCAqeq

The FDA has granted IND clearance for CT071, an autologous CAR T-cell therapy candidate targeting GPRC5D, for the treatment of patients with relapsed/refractory multiple myeloma (MM) or relapsed/refractory primary plasma cell leukemia (PCL).

CT071 is manufactured with CARsgen's proprietary CARcelerate™ platform, which shortens the manufacturing time to less than 2 days and therefore yields younger, healthier, and possibly more potent CAR T cells compared to conventional manufacturing. 

https://lnkd.in/gjx2kUiH

#cartcelltherapy #GPRC5D #CARcelerate

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables
accumulated other comprehensive income loss					1.80M -
cash and cash equivalents	96.48M -	1.04B 981.07%	691.28M 33.72%	2.27B 228.09%	1.85B 18.44%
cash and short term investments	96.48M -	1.04B 981.07%	3.01B 188.31%	2.27B 24.57%	1.85B 18.44%
common stock			1K -	1K 0%	1K 0%
deferred revenue
deferred revenue non current	15.72M -	13.17M 16.24%	15.12M 14.80%	21.18M 40.12%	188.83M 791.54%
deferrred tax liabilities non current					-188.83K -
goodwill
goodwill and intangible assets	35.47M -	30.46M 14.11%	26.92M 11.63%	21.11M 21.59%	15.13M 28.30%
intangible assets	35.47M -	30.46M 14.11%	26.92M 11.63%	21.11M 21.59%	15.13M 28.30%
inventory					683K -
long term debt	21.33M -	26.00M 21.90%	104.69M 302.69%	97.46M 6.90%	70.47M 27.70%
long term investments
net debt	-12.15M -	-942.71M 7,658.94%	-353.24M 62.53%	-2.15B 508.25%	-1.76B 17.87%
net receivables					22.63M -
other assets
other current assets			22.03M -		22.65K -
other current liabilities	958.37M -	70.97M 92.59%	155.81M 119.55%	149.02M 4.36%	181.47M 21.77%
other liabilities
other non current assets	10.77M -	9.34M 13.32%	23.10M 147.34%	4.21M 81.77%	12.76M 202.97%
other non current liabilities		2.75B -			188.83K -
othertotal stockholders equity	26.15M -	146.68M 460.90%	3.00B 1,943.06%	9.92B 230.88%	9.99B 0.75%
preferred stock
property plant equipment net	164.57M -	158.25M 3.84%	384.77M 143.13%	436.86M 13.54%	356.23M 18.46%
retained earnings	-758.75M -	-1.82B 140.24%		-7.44B -	-8.19B 10.05%
short term debt	63M -	74.26M 17.87%	233.36M 214.24%	21.98M 90.58%	14.75M 32.90%
short term investments			2.32B -
tax assets
tax payables	495K -	1.80M 264.65%	10.27M 468.70%	5.43M 47.05%	2.62M 51.78%
total assets	325.81M -	1.25B 284.84%	3.51B 179.59%	2.76B 21.19%	2.26B 18.30%
total current assets	115M -	1.06B 818.08%	3.07B 190.86%	2.30B 25.08%	1.87B 18.58%
total current liabilities	1.02B -	145.23M 85.78%	389.17M 167.97%	171.00M 56.06%	196.22M 14.74%
total debt	84.33M -	100.26M 18.89%	338.05M 237.18%	119.44M 64.67%	85.22M 28.65%
total investments			2.32B -
total liabilities	1.06B -	2.93B 176.83%	508.98M 82.63%	289.64M 43.09%	455.51M 57.27%
total liabilities and stockholders equity	325.81M -	1.25B 284.84%	3.51B 179.59%	2.76B 21.19%	2.26B 18.30%
total non current assets	210.81M -	198.06M 6.05%	434.78M 119.52%	462.18M 6.30%	384.13M 16.89%
total non current liabilities	37.05M -	2.78B 7,417.20%	119.80M 95.70%	118.64M 0.97%	259.30M 118.56%
total stockholders equity	-732.60M -	-1.68B 128.79%	3.00B 278.78%	2.47B 17.47%	1.80B 27.15%

2171

COM:CARSGEN

CARsgen Therapeutics

Last Close

7.02

25/11 08:08

Market Cap

2.36B

Beta: -

Volume Today

8.53M

Avg: -

Preview